Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

The Lancet Haematology

Volumn 6, Issue 12, 2019, Pages e630-e637

  Ahmed, Asra ^a   Merrill, Samuel A ^b   Alsawah, Fares ^c   Bockenstedt, Paula ^a   Campagnaro, Erica ^a   Devata, Sumana ^a   Gitlin, Scott D ^a   Kaminski, Mark ^a   Cusick, Alice ^a   Phillips, Tycel ^a   Sood, Suman ^a   Talpaz, Moshe ^a   Quiery, Albert ^a   Boonstra, Philip S ^d   Wilcox, Ryan A ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; BIOLOGICAL MARKER; CD163 ANTIGEN; CORTICOSTEROID; ETOPOSIDE; FERRITIN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; PREDNISONE; RUXOLITINIB; STAT1 PROTEIN; TACROLIMUS; TOCILIZUMAB; PYRAZOLE DERIVATIVE;

ADULT; ARTICLE; CANDIDIASIS; CASE REPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE EXACERBATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMOPHAGOCYTIC SYNDROME; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; MACULOPAPULAR RASH; MIDDLE AGED; MONOCYTE; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHARMACODYNAMICS; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; MALE; MORTALITY; NEUTROPHIL; PATHOLOGY; PLATELET COUNT; SPLENOMEGALY; SURVIVAL ANALYSIS;

ADULT; FEMALE; HISTORICALLY CONTROLLED STUDY; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; NEUTROPHILS; PILOT PROJECTS; PLATELET COUNT; PYRAZOLES; SPLENOMEGALY; SURVIVAL ANALYSIS;

EID: 85075336167     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(19)30156-5     Document Type: Article

References (30)

1. Chandrakasan, S, Filipovich, AH, Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr 163 (2013), 1253–1259.
2. Schram, AM, Berliner, N, How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125 (2015), 2908–2914.
3. Henter, JI, Samuelsson-Horne, A, Arico, M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100 (2002), 2367–2373.
4. Bergsten, E, Horne, A, Arico, M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130 (2017), 2728–2738.
5. Schram, AM, Comstock, P, Campo, M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol 172 (2016), 412–419.
6. Parikh, SA, Kapoor, P, Letendre, L, Kumar, S, Wolanskyj, AP, Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 89 (2014), 484–492.
7. Riviere, S, Galicier, L, Coppo, P, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med 127 (2014), 1118–1125.
8. Li, J, Wang, Q, Zheng, W, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine 93 (2014), 100–105.
9. Merrill, SA, Naik, R, Streiff, MB, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine, 97, 2018, e11579.
10. Jordan, MB, Hildeman, D, Kappler, J, Marrack, P, An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104 (2004), 735–743.
11. Pachlopnik Schmid, J, Ho, CH, Chretien, F, et al. Neutralization of IFN gamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 1 (2009), 112–124.
12. Das, R, Guan, P, Sprague, L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127 (2016), 1666–1675.
13. Wang, T, Feldman, AL, Wada, DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 123 (2014), 3007–3015.
14. Cetica, V, Santoro, A, Gilmour, KC, et al. STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. J Med Genet 47 (2010), 595–600.
15. Meeths, M, Entesarian, M, Al-Herz, W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood 116 (2010), 2635–2643.
16. Schaer, DJ, Schleiffenbaum, B, Kurrer, M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 74 (2005), 6–10.
17. Tamamyan, GN, Kantarjian, HM, Ning, J, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes. Cancer 122 (2016), 2857–2866.
18. Johnson, TS, Terrell, CE, Millen, SH, Katz, JD, Hildeman, DA, Jordan, MB, Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol 192 (2014), 84–91.
19. Akashi, K, Hayashi, S, Gondo, H, et al. Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 87 (1994), 243–250.
20. Bracaglia, C, de Graaf, K, Pires Marafon, D, et al. Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 76 (2017), 166–172.
21. Osugi, Y, Hara, J, Tagawa, S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89 (1997), 4100–4103.
22. Takada, H, Takahata, Y, Nomura, A, Ohga, S, Mizuno, Y, Hara, T, Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol 133 (2003), 448–453.
23. Tefferi, A, Pardanani, A, Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 1 (2015), 97–105.
24. Verstovsek, S, Kantarjian, H, Mesa, RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363 (2010), 1117–1127.
25. Forbes, LR, Vogel, TP, Cooper, MA, et al. Jakinibs for the treatment of immunodysregulation in patients with gain of function STAT1 or STAT3 mutations. J Allergy Clin Immunol 142 (2018), 1665–1669.
26. Broglie, L, Pommert, L, Rao, S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv 1 (2017), 1533–1536.
27. Sin, JH, Zangardi, ML, Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther, 2017 published online Aug 16. DOI:10.1016/j.hemonc.2017.07.002.
28. Slostad, J, Hoversten, P, Haddox, CL, Cisak, K, Paludo, J, Tefferi, A, Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience. Am J Hematol 93 (2018), e47–e49.
29. Zandvakili, I, Conboy, CB, Ayed, AO, Cathcart-Rake, EJ, Tefferi, A, Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience. Am J Hematol 93 (2018), e123–e125.
30. Tefferi, A, Pardanani, A, Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86 (2011), 1188–1191.